38 articles for RJ DeVita
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
3
Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds.
TBA
6
Discovery of a Potent and Selective DGAT1 Inhibitor with a Piperidinyl-oxy-cyclohexanecarboxylic Acid Moiety.
Merck Research Laboratories
8
Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain.
Merck Research Laboratories
21
Potent DGAT1 Inhibitors in the Benzimidazole Class with a Pyridyl-oxy-cyclohexanecarboxylic Acid Moiety.
Merck Research Laboratories
2
2-[(3aR,4R,5S,7aS)-5-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyethoxy}-4-(2-methylphenyl)octahydro-2H-isoindol-2-yl]-1,3-oxazol-4(5H)-one: a potent human NK1 receptor antagonist with multiple clearance pathways.
Merck Research Laboratories
17
Discovery of MK-3168: A PET Tracer for Imaging Brain Fatty Acid Amide Hydrolase.
Merck Research Laboratories
2
Multiple strategies for the preparation of a sulfur-35 labeled NPC1L1 radioligand.
Merck Research Laboratories
16
Fused bicyclic pyrrolizinones as new scaffolds for human NK1 antagonists.
Merck Research Laboratories
80
Spiroimidazolidinone NPC1L1 inhibitors. Part 2: structure-activity studies and in vivo efficacy.
Merck
19
Fused tricyclic pyrrolizinones that exhibit pseudo-irreversible blockade of the NK1 receptor.
Merck Research Laboratories
14
Substituted fused bicyclic pyrrolizinones as potent, orally bioavailable hNK1 antagonists.
Merck Research Laboratories
10
Spiroimidazolidinone NPC1L1 inhibitors. 1: Discovery by 3D-similarity-based virtual screening.
Merck
8
Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists.
Merck Research Laboratories
24
Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.
Merck Research Laboratories
29
The discovery of potent, selective, and orally bioavailable hNK1 antagonists derived from pyrrolidine.
Merck
10
DYRK1A Inhibitors as Potential Therapeutics for β-Cell Regeneration for Diabetes.
Icahn School Of Medicine At Mount Sinai
32
2-Aminoquinoline melanin-concentrating hormone (MCH)1R antagonists.
Merck Research Laboratories
55
4-Aminoquinoline melanin-concentrating hormone 1-receptor (MCH1R) antagonists.
Merck Research Laboratories
16
Identification of neutral 4-O-alkyl quinolone nonpeptide GnRH receptor antagonists.
Merck Research Laboratories
15
Syntheses and structure-activity relationship studies of piperidine-substituted quinolones as nonpeptide gonadotropin releasing hormone antagonists.
Merck
1
A potent, nonpeptidyl 1H-quinolone antagonist for the gonadotropin-releasing hormone receptor.
Merck Research Laboratories
56
Quinolones as gonadotropin releasing hormone (GnRH) antagonists: simultaneous optimization of the C(3)-aryl and C(6)-substituents.
Merck Research Laboratories
26
Potent antagonists of gonadotropin releasing hormone receptors derived from quinolone-6-carboxamides.
Merck Research Laboratories
27
Identification of CNS-Penetrant Aryl Sulfonamides as Isoform-Selective Na
Xenon Pharmaceuticals
8
Investigation of the 4-O-alkylamine substituent of non-peptide quinolone GnRH receptor antagonists.
Merck Research Laboratories
22
Identification and initial structure-activity relationships of a novel non-peptide quinolone GnRH receptor antagonist.
Merck Research Laboratories
21
Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor.
Icahn School Of Medicine At Mount Sinai
11
Development of indazole mineralocorticoid receptor antagonists and investigation into their selective late-stage functionalization.
Merck
6
Benzimidazole-based DGAT1 inhibitors with a [3.1.0] bicyclohexane carboxylic acid moiety.
Merck
26
Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.
Icahn School Of Medicine At Mount Sinai
12
Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation.
TBA
50
Microscale High-Throughput Experimentation as an Enabling Technology in Drug Discovery: Application in the Discovery of (Piperidinyl)pyridinyl-1H-benzimidazole Diacylglycerol Acyltransferase 1 Inhibitors.
Merck
136
IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY
Imperial College Innovations
12
Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
Pfizer